[Local transcatheter arterial chemoembolization in the palliative treatment of inoperable XXXX ].

@entity1 @entity5572 @entity5 @entity189 @entity1578 @entity158 @entity432 @entity157 @entity4854 @entity413
@entity157 is a @entity5 with high mortality. Adequate oncological therapy is essential to modify the poor prognosis. Transcatheter @entity432 has been proposed as a useful and well-tolerated treatment for unresectable @entity189 . In the study 51 @entity1 with unresectable @entity189 (mean age 61.6, range 45-81, @entity1 -Pugh A = 34 @entity1 , @entity1 -B = 13, @entity1 -C = 4; Okuda I = 33 @entity1 , Okuda II = 18) underwent chemoembolisation. A total of 122 procedure were performed, with a median number of 2.4 (range 1-6) per @entity1 . One and two year survivals are 91% and 74% respectively ( @entity1 -A: 100% and 82%; @entity1 -B: 100% and 63%; @entity1 -C 0% at 1 year). The difference among the 3 groups is statistically significant (p = 0.001). Median overall survival is 20 months, with 22, 20 and 6 month in @entity1 -A, B and C @entity1 respectively (p = 0.006). Commonly reported side effects and biochemical changes included: fever, @entity158 and increased serum amylase, transaminase levels. One @entity1 developed a @entity5572 and died of @entity1578 . In addition, in 18 @entity1 (35%) mild to severe changes in @entity413 metabolism were also observed. Mild @entity4854 was observed in 14 @entity1 , with severe derangement in 4 @entity1 (8%). It is suggested that careful evaluation of @entity413 metabolism is advisable in @entity1 being considered for chemoembolisation. Their results confirm the usefulness of chemoembolisation in @entity1 -A and B @entity1 with unresectable @entity157 .
